ArticleTranslational cancer research2025
The relationship and predictive efficacy of serum lipocalin-2, PDK1, NGALR and lymph node metastasis in postmenopausal endometrial cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial carcinoma is a common gynecological malignancy, LNM is a crucial factor affecting the prognosis of endometrial cancer patients, with a significant impact on survival rates and treatment effectiveness. Serum lipocalin-2, PDK1, and NGALR have been found to be abnormally expressed in various tumors and are potentially associated with tumor metastasis. Therefore, this study aims to investigate these relationships and evaluate the predictive efficacy of these biomarkers, which may provide new insights and methods for the early diagnosis and treatment of postmenopausal endometrial cancer with LNM. Methods: Totally 133 postmenopausal endometrial cancer patients treated in Harbin Medical University Cancer Hospital and 100 healthy subjects were included in this study. According to the postoperative pathological diagnosis, 133 patients were divided into LNM group (n=47) and non LNM group (n=86). Results: The serum lipocalin-2, PDK1, and NGALR levels in patients with endometrial cancer were significantly higher than those in the healthy group (P<0.05). The results of logistic regression analysis showed that the lipocalin-2, PDK1, and NGALR were all factors affecting LNM (P<0.05). Area under the curve (AUC) of lipocalin-2, PDK1 and NGALR were 0.755, 0.778 and 0.856 respectively by establishing receiver operating characteristic (ROC) curve analysis, with the specificity of 67.50%, 67.50% and 82.50%, respectively. The sensitivities were 80.00%, 82.22% and 75.56%, respectively. The AUC (0.925), sensitivity (98.89%) and specificity (70.00%) of the joint tests were higher than those of the other three tests. The joint tests had higher diagnostic value for LNM of postmenopausal endometrial carcinoma. Conclusions: The serum levels of lipocalin-2, PDK1, and NGALR in postmenopausal endometrial carcinoma patients and patients with LNM were significantly increased, and the combined detection had higher diagnostic value for postmenopausal endometrial carcinoma LNM, which would be beneficial to guide the diagnosis and treatment of postmenopausal endometrial carcinoma LNM in clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.